Lenvatinib administered to patients with unresectable HCC who were unresponsive to PD-1/PD-L1 checkpoint blockade demonstrated considerable antitumor activity and a tolerable safety profile. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.